2020 “Yinhua Fund Cup” Sina bank financial planner competition, hot registration. From now on to September 7, you will receive free gift packages worth more than 700 yuan from Guan Qingyou, Luo Yuanshang, Chen Kaifeng and Jian Qi. < p > < p > Beijing News (reporter Wang Kara) on August 20, Zhengchuan Co., Ltd. released the semi annual report of 2020. Under the influence of Xinguan epidemic, the demand of pharmaceutical enterprises fluctuated, and the business performance was affected to a certain extent. During the reporting period, Zhengchuan shares achieved revenue of 256 million yuan, a year-on-year decrease of 4.46%; the net profit attributable to shareholders of listed companies was 34.92 million yuan, with a year-on-year increase of 9.22%. Zhengchuan Co., Ltd. is specialized in the R & D, production and sales of pharmaceutical packaging materials such as pharmaceutical glass tube bottles. The products are mainly used for the inner packaging of biological agents, traditional Chinese medicine preparations, water injection, powder injection, oral liquid of chemical medicine preparations and health care products. It is one of the leading enterprises in the domestic pharmaceutical glass control bottle subdivision industry. In the first half of this year, Zhengchuan introduced foreign first-class kiln technology and equipment, and the construction project of China borosilicate glass furnace was smoothly promoted, and it is expected to be put into production in the second half of this year. After being put into production, the company will have the production capacity of borosilicate glass tubes, which is expected to realize import substitution. The borosilicate glass bottle is more stable, and it is the packaging material of new crown vaccine recognized by the industry. < p > < p > on July 30 this year, Zhengchuan Co., Ltd. announced that the company plans to issue convertible bonds to raise no more than 405 million yuan, which will be used in the production project of China borosilicate medical glass and the research project of compatibility between China borosilicate medical glass and medicine, of which 375 million yuan is planned to be used for the production project of China borosilicate (with a total investment of 404.3 million yuan), with a construction period of 2 years, and the annual output of 1.3 billion pieces can be formed after the project reaches its capacity Production capacity of medium borosilicate glass bottles. According to Zhengchuan Co., Ltd., from the long-term development trend of foreign pharmaceutical glass industry, high-quality medium borosilicate glass will gradually replace low borosilicate glass and sodium calcium glass in the future and become the choice material for domestic pharmaceutical packaging. < p > < p > since this year, the world has been paying attention to the research and development of the new crown vaccine, and the news that “vaccine glass bottle is in short supply” has caused the capital market to pay attention to the relevant listed companies. China Vaccine Industry Association pointed out in the official micro blog in May this year that the packaging materials selected for the particularity of vaccines are borosilicate glass, mainly controlled injection bottles (commonly known as “penicillin bottles”) and pre filling syringes. < p > < p > the speculation of hot topics continuously pushed up the stock price of Zhengchuan. Since May this year, the company’s stock price has risen from the opening price of 17.02 yuan / share on May 6 to 108 yuan / share on August 4, constantly refreshing the highest stock price in history. However, after hitting an all-time high on August 4, share prices began to fall. On August 20, the stock price closed at 68.57 yuan / share, up 302.88% in more than three months. However, Zhengchuan Co., Ltd. has issued announcements for many times, saying that the company has not received the batch purchase order of vaccine bottles rumored in the relevant market, and only produces the medium borosilicate glass bottles by outsourcing the medium borosilicate glass tubes, and the proportion of the medium borosilicate glass bottles in the company’s product structure is relatively low. A medium borosilicate glass tube furnace of the company is under construction and has not been put into mass production. Even if the formal mass production, the production is relatively limited, and the market share is not high in the short term. At the same time, the consistency evaluation carried out by the state, the stability test of drug packaging materials and so on need to be verified for a long time. It is uncertain whether the borosilicate glass tube produced by the company can be used for vaccine in the future. The Beijing News reporter also noted that since May this year, several directors and senior supervisors of Zhengchuan Stock Co., Ltd. have reduced their holdings to cash out. Among them, Deng Bujian, the supervisor of the company, reduced 19000 shares of the company and realized 46659 yuan of cash; fan Yong and Li Zhengde, the directors and supervisors, planned to reduce their holdings of no more than 60000 shares and 14000 shares respectively, realizing 182000 yuan and 420000 yuan; Xiao Qing, the director and senior supervisor, realized 105638 yuan. On July 30, sun Lianyun and Qin Feng, the senior supervisors of the board of directors, proposed to reduce their holdings by no more than 4300 shares and 4000 shares respectively; on August 4, Xiao Qing, the senior supervisor of the board of directors, put forward the reduction plan again with a planned reduction of no more than 15700 shares; and Gao jiangfeng’an, the director of the board of directors, also planned to reduce his holdings by no more than 35100 shares. According to the announcement issued by Zhengchuan on August 19, the company will have more than 112 million restricted shares listed on August 24, accounting for 74.67% of the total share capital of the company, involving 12 shareholders, including Xiao Qing, Jiang Fengan, Li Zhengde, fan Yong, etc.